Seaport Therapeutics’ IPO aims to fund prodrug R&D for neuropsychiatric disorders. Read the full analysis here.

Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...

Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets. | Seaport Therapeutics and Hemab Therapeutics are both charting a course for the public markets.

Seaport Therapeutics has filed to go public. The buzzy Boston biotech was founded by the same team behind the local success story Karuna Therapeutics, which was bought by Bristol Myers Squibb for $14 ...

Seaport Therapeutics filed for an initial public offering. The clinical-stage therapeutics company is focused on inventing and developing medicines for patients with depression, anxiety and other ...

The team behind The Banks, Bistro du Midi, Grill 23, and Harvest have splashy plans for Boston’s Seaport. Himmel Hospitality ...

Broadcom (NASDAQ:AVGO) stock received a notable vote of caution this week when Seaport Global Securities downgraded Broadcom ...